Search
Atopic Dermatitis Paid Clinical Trials in Wisconsin
A listing of 6 Atopic Dermatitis clinical trials in Wisconsin actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 6 of 6
The state of Wisconsin currently has 6 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Milwaukee, Madison, Green Bay and Marshfield.
Featured Trial
Atopic Dermatitis Clinical Study
Recruiting
We are looking for people who are diagnosed with atopic dermatitis to join our latest clinical research study. Help us as we aim to find out more about an investigational medication for atopic dermatitis.
Payment up to $1300, which varies by study
Compensation for time and study-related travel
Study medication at no cost
Study-related care from specialist doctors
Payment up to $1300, which varies by study
Compensation for time and study-related travel
Study medication at no cost
Study-related care from specialist doctors
Conditions:
Atopic Dermatitis
Atopic
Dermatitis
Atopic
Atopic Dermatitis Eczema
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Dilated Cardiomyopathy (DCM) Research Study
Recruiting
If you are identified as eligible for investigational genetic testing, you will be sent a saliva collection kit to your home. Once you have completed and returned your kit to Sano Genetics, your sample will be tested for a specific genetic pathway called BAG3.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Conditions:
Dilated Cardiomyopathy (DCM)
Cardiovascular Diseases
Cardiomyopathy
Cardiovascular Disease
Heart Failure
Featured Trial
Parkinson's Disease: Genetic Testing and Clinical Trial
Recruiting
Sano is launching a new study to understand the genetics of Parkinson’s and give researchers the data they need to better understand this condition. By participating, you will support cutting-edge research and help pave the way for future breakthroughs. You may be referred to participate in a clinical trial.
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
Conditions:
Parkinson's Disease
Parkinson Disease
Parkinson's Disease (PD)
Idiopathic Parkinson's Disease
Parkinsonian Disorders
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
06/25/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Atopic Dermatitis, Eczema
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Recruiting
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/25/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Atopic Dermatitis
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
Recruiting
This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and adolescents with atopic dermatitis who are culture positive for S. aureus colonization.
The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which inclu... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: University of Wisconsin School of Medicine and Public Health: Division of Pediatric Allergy, Immunology and Rheumatology, Madison, Wisconsin
Conditions: Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/18/2025
Locations: Wisconsin Medical Center /ID# 267236, Milwaukee, Wisconsin
Conditions: Atopic Dermatitis
Systems Biology of Early Atopy
Recruiting
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions.
Primary Objectives:
* To study the role and interrelationships of established and novel clinical, environmental, biological, a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
05/13/2025
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2025
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
1 - 6 of 6